Eluminex Biosciences is committed towards developing first- and/or best-in-class innovative treatments for ophthalmic diseases.
Global partnerships provide the opportunity for us to continue to build an innovative ophthalmic portfolio and offer an entry point for the development of new drugs for China, the largest patient population in the world, and beyond.
With extensive experience in ophthalmic drug development, our team can help maximize the value of an emerging asset under a working partnership towards a shared goal of benefiting patients with vision-threatening or lifestyle limiting disease. If you have a novel drug candidate or an innovative approach in ocular drug delivery, Eluminex Biosciences can help mutually develop the next generation of ophthalmic therapeutics. We want to hear from you.